Lee Gyeong-Won, Kang Jung Hun, Kim Hun-Gu, Lee Jong-Sil, Lee Jong-Seok, Jang Joung-Soon
Department of Internal Medicine, College of Medicine, Gyeong-Sang National University, Jinju, Korea.
Am J Clin Oncol. 2006 Apr;29(2):127-31. doi: 10.1097/01.coc.0000203742.22828.bb.
The aim of this study was to determine the efficacy and safety profile of gemcitabine plus cisplatin in patients with immunohistochemically proven unresectable cholangiocarcinoma.
Between March 2002 and December 2004, a total of 24 patients with immunohistochemically proven cholangiocarcinoma were entered in this study. Treatment consisted of gemcitabine 1000 mg/m2 intravenous infusion on day 1 and 8 and cisplatin 70 mg/m2 intravenously on day 1 every 3 weeks.
Seventy-one cycles of treatment were given, with a median of 3 cycles (range, 2-6 cycles). Five patients had a partial response (PR), 12 patients had stable disease (SD), and 7 patients progressed during treatment. A median survival of 9.30 months (range, 6.43-12.17) was obtained hematologic and nonhematologic toxicities were generally acceptable. However, there was one treatment-related mortality caused by thrombotic thrombocytopenia purpura (TTP) associated with gemcitabine and cisplatin.
The combination chemotherapy of gemcitabine and cisplatin had a modest effect and was a well tolerated treatment of patients with immunohistochemically proven metastatic or unresectable cholangiocarcinoma.
本研究旨在确定吉西他滨联合顺铂对免疫组化证实为不可切除胆管癌患者的疗效和安全性。
2002年3月至2004年12月，共有24例免疫组化证实为胆管癌的患者纳入本研究。治疗方案为每3周一次，第1天和第8天静脉输注吉西他滨1000mg/m²，第1天静脉输注顺铂70mg/m²。
共进行了71个周期的治疗，中位周期数为3个周期（范围2 - 6个周期）。5例患者部分缓解（PR），12例患者疾病稳定（SD），7例患者在治疗期间病情进展。中位生存期为9.30个月（范围6.43 - 12.17个月），血液学和非血液学毒性一般可接受。然而有1例与吉西他滨和顺铂相关的血栓性血小板减少性紫癜（TTP）导致的治疗相关死亡。
吉西他滨和顺铂联合化疗有一定疗效，是免疫组化证实的转移性或不可切除胆管癌患者耐受性良好的治疗方法。
